Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Liraglutide

Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes

Novo Nordisk · Phase 3 · Completed · Enrollment 3731

NCT01272219

EudraCT 2008-001049-24

ArmPopulationDoseWeeksEstimandWeight change
Liraglutide 3.0mg (week0-56)/Liraglutide 3.0mg (week56-68)Obesity or overweight3.0mg68n/r0.69% at week 56
Liraglutide 3.0mg (week0-56)/Liraglutide Placebo (week56-68)Obesity or overweight3.0mg68n/r2.91% at week 56
Liraglutide Placebo, no Pre-diabetesObesity or overweightn/r68n/r0.28% at week 56
Liraglutide 3.0mg, Pre-diabetesObesity or overweight3.0mg68n/rn/r
Liraglutide Placebo, Pre-diabetesObesity or overweightn/r68Efficacyn/r
Liraglutide 3.0 mg (56-Week)Obesity or overweight3.0 mg56Efficacyn/r